Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied. METHODS We conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square of the height in meters] of ≥30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned, in a 2:1 ratio, to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling on physical activity and a reduced-calorie diet. The primary end points were the percentage change in body weight and the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score (on a scale of 0 to 100, with higher scores reflecting worse outcomes) from baseline to week 68. A key confirmatory secondary end point was the physical-function score on the 36-Item Short Form Health Survey (SF-36), version 2 (on a scale of 0 to 100, with higher scores indicating greater well-being). RESULTS A total of 407 participants were enrolled. The mean age was 56 years, the mean BMI 40.3, and the mean WOMAC pain score 70.9. A total of 81.6% of the participants were women. The mean change in body weight from baseline to week 68 was -13…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Semaglutide (2•4 mg/week) has been shown to cause symptomatic improvement related to moderate knee osteoarthritis as well as bodyweight reduction.89”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [89]
In the citing paper
“In a 68-week clinical trial involving individuals with obesity and knee osteoarthritis with moderate to severe pain (STEP-9), semaglutide treatment led to a greater reduction in the Western Ontario and McMaster Universities Osteoarthritis Index score (–41.7 points) as compared with placebo (–27.5 points) (88).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“In the STEP-9 trial, use of semaglutide led to greater weight loss and improvements in knee pain and physical function compared to placebo in patients with obesity and moderate-to-severe osteoarthritis-related symptoms.45”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [45]
In the citing paper
“In the STEP 9 trial involving adults with obesity and knee osteoarthritis, semaglutide resulted in significantly greater weight loss (− 13.7% vs. −3.2%), pain reduction (WOMAC − 41.7 vs. −27.5 points), and improvement in physical function (SF-36 + 12.0 vs. +6.5 points) compared to placebo (all P < 0.001) at 68 weeks, with a similar rate of serious adverse events [63].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [63]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationHunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis
Kohn, M. D., Sassoon, A. A., & Fernando, N. D. (2016) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-016-4732-4 · Cited by 1,459
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 201–300 of 438
Current and future advances in practice: practical management of hand osteoarthritis
Watt, F. E., Kennedy, D. L., Gardiner, M. D., & Vincent, T. L. (2025) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaf093 · Cited by 1
“So far, trials have been focused on the knee and have shown pain reduction [86].”
Hussain, M., & Miras, A. D. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02402-z · Cited by 3
Meng, Y., Jin, T., Ren, L., Thompson, M. L., & Wang, Y. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0033 · Cited by 1
Palmer, R. C., Telang, S. S., Kistler, N. M., Mayfield, C. K., Hong, K. M., Gucev, G., Lieberman, J. R., & Heckmann, N. D. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04604-x · Cited by 2
Elingaard-Larsen, L. O., Whytock, K. L., Divoux, A., Ahn, C., Distéfano, G., Goodpaster, B. H., Coen, P. M., Justice, J. N., Kershaw, E. E., Lane, N. E., et al. (2025) · Aging Cell · doi:10.1111/acel.70348 · Cited by 4
“A recent study showed that a 26-week GLP-1 receptor agonist treatment in obese individuals with KOA and knee pain significantly reduced knee pain, which could only partly be explained by the coinciding weight loss (Henning et al. 2024).”
Luo, F., Guo, J.-J., Jiang, F.-Z., Yuan, X., Zhou, H., Wang, Q.-Y., Chen, C.-M., Yao, X.-M., & Ma, W. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01082-8 · Cited by 1
“Obesity plays a bimodal etiological role in OA through biomechanical loading of articular structures and adipokine-driven meta-inflammatory cascades [31, 32].”
Metabolic Optimization Before Orthobiologic Therapies (MOBOT): A Narrative Review
Fernandes, G. C. D. A. M., & Rodeo, S. A. (2026) · Sports Health A Multidisciplinary Approach · doi:10.1177/19417381251409133 · Cited by 2
“6 These benefits may optimize the biological environment for regenerative therapies, particularly in metabolically unhealthy people.”
Cochrane, J. A., Roberts, O. L., Ribbons, K., Clark, R., Pua, Y. H., Tan, T. L., Thwin, L., Leung, Y. Y., Liow, M. H. L., Tan, B. Y., et al. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x251407070 · Cited by 1
“5 The current therapeutic strategies are not curative but are targeted at the amelioration of disease symptoms and attenuation of disease progression.”
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Harris, M., Brown, J., & Renehan, A. G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03355-8 · Cited by 1
“RCTs demonstrate their bene fi ts beyond weight loss, on reducing the risk of obesity-related co-morbidities such as type 2 diabetes [15], cardiovascular events [16], renal function [17], and osteoarthritis [18].”
Majumdar, N., Pokharel, B. R., Williams, F., Rajput, S., Cook, P., & Akula, S. M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07922-8 · Cited by 1
“Obesity is either a direct cause or a contributing factor in several serious health conditions, including cardio-vascular disease [16], diabetes [17], certain cancers [18, 19], arthritis [20], sleep apnea [21], and premature death [22].”
Cao, M., Lin, C., Cai, X., Lv, F., Yang, W. B., & Ji, L. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261428147 · Cited by 3
“11 Thus, the exact impact of GLP-1R–based agonists on osteoarthritis requires further investigation.”
Joyce, M. R., Muccini, J., Randoing, B., Delp, S. L., & Uhlrich, S. D. (2026) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2026.3669842 · Cited by 2
“While additional studies are needed, this work demonstrates the promise of low-cost, non-surgical interventions—such as muscle coordination retraining—to address a critical treatment gap for individuals with mild-to-moderate knee osteoarthritis.”
The Role of Fat in Osteoarthritis
Collins, K. H. (2026) · Journal of Orthopaedic Research® · doi:10.1002/jor.70168 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Troshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
Ford, K., Achenbach, A., & Buckwalter, K. C. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105763 · Cited by 1
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Hu, D., Sun, Y., Lu, Q., Zhang, Y., Li, J., Hou, H., Wang, H., Tang, H., Zhang, Y., Zheng, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202523949 · Cited by 2
“Moreover, a clinical trial has shown that treatment with weekly injections of semaglutide (a GLP-1 analogue) can significantly reduce knee pain in patients with obesity and knee osteoarthritis [ 28 ].”
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Wang, W., Fortuna, R., Mayengbam, S., Seerattan, R. A., Mu, C., Rios, J. L., Abughazaleh, N., Vaghef‐Mehrabany, E., Tuplin, E. W. N., Hart, D. A., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2679516 · Cited by 2
“3,5 ,8-11 For instance, metformin, a widely used diabetes medication, has exhibited favorable effects on OA symptoms and progression in placebo-controlled trials of patients with knee OA and comorbid obesity, 3,10 as well as in a large-scale propensity score–matched cohort study involving patients…”
Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis
Tian, Y., Zheng, Z., Ma, Y., Ye, F., Pang, Y., Zhang, Z., Li, Z., Zhang, C., & Gao, J. (2026) · iScience · doi:10.1016/j.isci.2026.116347 · Cited by 1
Bugajewski, M., Stolarczyk, A., Matysek, M., Adamus, J. P., Poszytek, A., & Pączek, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125292 · Cited by 1
“GLP-1 receptor agonists have shown greater reductions in body weight and OA-related pain than placebo in patients with knee OA [125].”
Simon, A., Simon, V., Alimy, A., Schleid, K., Ocokoljic, A., Bartosik, M., Kroge, S. V., Mussawy, H., Amling, M., Beil, F. T., et al. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.06.035 · Cited by 2
Effects of Metabolic Dysregulation on Macrophage Polarization in Rheumatoid Arthritis
Zhang, X.-Y., Deng, X.-Y., Wei, S.-X., Li, M.-T., & Zeng, X.-F. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70253 · Cited by 2
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Grigson, P. S., Bunce, S. C., Brick, T. R., Freet, C. S., Nyland, J. E., Kawasaki, S. S., Brandl, C. G., Shealy, E., & Huddleston, K. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.033 · Cited by 2
Angelopoulos, A., Fragoulis, G., Papagoras, C., & Daoussis, D. (2026) · Rheumatology International · doi:10.1007/s00296-026-06258-2 · Cited by 1
Shrestha, R., Kovacevich, A., Yerneni, H., Shroff, P., & Sajatovic, M. (2026) · Psychiatric Annals · doi:10.3928/00485713-20260701-01 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Grave, R. D. (2024) · IJEDO · doi:10.32044/ijedo.2024.02 · Cited by 1
Associations Between Common Hip and Knee Osteoarthritis Treatments and All-Cause Mortality
Orchard, J. W., Tutt, L. E., Hines, A., & Orchard, J. J. (2025) · Healthcare · doi:10.3390/healthcare13172229 · Cited by 2
“…knee OA in overweight patients is Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as not only have these been proven to be effective for weight loss (which indirectly should help lower limb OA), there is already one high-quality randomised trial showing actual reductions in knee pain [15].”
New directions in childhood obesity treatment – A path forward or wishful thinking?
Reilly, J. L., Arora, S., Chatman, K., Cooper, Z., & Hsia, D. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.010 · Cited by 1
Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
Fernández, L. C., Pérez, J. S., Fernández, C. G., & Vela, N. S. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.2.art3 · Cited by 1
“La semaglutida utilizada como tratamiento para la obesidad ha demostrado reducir el dolor de los pacientes con artrosis de rodilla 26 .”
Shadbolt, C., & Dowsey, M. M. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.02.779 · Cited by 2
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis
Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.93373 · Cited by 5
Liu, W., Chen, X., Jiang, Z., Zhao, L., Jiang, K., Tang, R., Li, W., You, M., Zhou, H., Chen, H., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8147049/v1 · Cited by 3
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Anti-obesity drug has life-changing benefits for arthritis
Watson, T. (2024) · Nature · doi:10.1038/d41586-024-03512-0
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
Skowronek, A., Piekarska, M., Dąbek, K., Ochwat, M., Sudoł, M., Mierzwa, G., Kajtel, A., & Skowronek, T. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.56953
“[24] The study compared a group of patients using once-weekly injectable semaglutide for 68 weeks to a control group who were recommended exercise and a caloric deficit diet.”
Brève : Gonalgie soulagée après antiinflammatoire et perte de poids ?
Dalmat, Y.-M. (2025) · Option/Bio · doi:10.1016/s0992-5945(25)00016-9
(2025) · Bone and Joint 360 · doi:10.1302/2048-0105.141.360208
Semaglutid bei Adipositas plus Gonarthrose
Krome, S. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2467-6995
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Brève : Vous avez de l’arthrite ? Prenez un antidiabétique !
Manus, J.-M. (2025) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(25)00013-9
Avances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Vous avez de l'arthrite ? Prenez un antidiabétique !
Manus, J.-M. (2025) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(25)76341-8
The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis
Holleman, A. D., & Katz, J. N. (2025) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2025.100611
Singh, M. P., Yadav, R., & Singh, A. D. (2025) · Research Square · doi:10.21203/rs.3.rs-6482330/v1
Les meilleures études en 2024 adaptées aux soins primaires
Moe, S. S., Perry, D., Thomas, B. S., Nickonchuk, T., Braschi, É., Dugré, N., Finley, C. R., Lindblad, A. J., Potter, J., & Allan, G. M. (2025) · Canadian Family Physician · doi:10.46747/cfp.7105e77
Top studies of 2024 relevant to primary care
Moe, S. S., Thomas, B. S., Perry, D., Braschi, É., Dugré, N., Falk, J., Lindblad, A. J., Paige, A., & Allan, G. M. (2025) · Canadian Family Physician · doi:10.46747/cfp.7105309
Semaglutide settimanale per il trattamento della gonartrosi obesità-relata
Velardi, V., Candido, R., & Bernardi, S. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01640-x
Burden of Obesity in Adults at a Tertiary Care Hospital
Bukasa-Kakamba, J., Wadhwani, S., Malu, E. N., Wadhwani, N., Latil-Plat, F., Poka, N., Kalambayi, I. K., Mutombo, M. B., Mohamed, A., Bangolo, A., et al. (2025) · Cureus · doi:10.7759/cureus.84776 · Cited by 2
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease
Trinacty, J., & Rostom, K. (2025) · Canadian rheumatology today. · doi:10.58931/crt.2025.2158
Felson, D. T., & Berenbaum, F. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43275
Les analogues de GLP-1 dans l’arthrose : avancées et perspectives
Berenbaum, F. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.06.003
Quoi de neuf en rhumatologie ?
Moret, M. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.06.024
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347782
Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA
Blair, C. V., Huck, D. M., Besser, S. A., Cardoso, R. N., Shiyovich, A., Berman, A. N., Biery, D. W., Weber, B., Petranović, M., Nasir, K., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101995
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K. K., & Lee, S. W. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5372118
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rhouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E. D. F., et al. (2025) · medRxiv · doi:10.1101/2025.07.28.25332295
Ding, J., Yang, C., & Li, X. (2025) · CytoJournal · doi:10.25259/cytojournal_199_2024
“[6,7] One study showed that diabetes can increase perioperative blood loss and delay post-operative functional recovery after primary total knee arthroplasty.”
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Metformin for Treatment of Knee Osteoarthritis in Patients With Overweight or Obesity
Yen, H., Fu, S., & Chiang, C. (2025) · JAMA · doi:10.1001/jama.2025.10717
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Al‐Aly, Z. (2025) · The Conversation · doi:10.64628/aai.rk3cwuhxe · Cited by 1
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Obesity and musculoskeletal pain: possibilities of pharmacotherapy. A narrative overview
Karateev, A. E., & Zotkin, E. G. (2025) · Russian Journal of Pain · doi:10.17116/pain20252303173
What’s New in Orthopaedic Rehabilitation
Nakamura, R., Aagesen, A. L., Berri, H., Chandran, S., Kasitinon, D., Lewno, A. J., & Jain, N. B. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.00796
Montero, A. A., & Vidal, P. J. I. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102598
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Umesh, A., Cordogan, S., Simpson, S. K., Bram, J. T., Jones, R. H., Schairer, W. W., Sboner, A., Elemento, O., Green, D. W., & Fabricant, P. D. (2025) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003679 · Cited by 2
Brødsgaard, R. H., Dirksen, C., Pedersen, M. M., Kirk, J. W., Duun, O. M., Finken, M. T., Bojsen-Møller, K. N., & Bandholm, T. (2025) · medRxiv · doi:10.1101/2025.10.20.25337060
“Large-scale pharmaceutical trials have demonstrated the effectiveness of GLP-1RAs in reducing weight and disease-specific symptoms and risks in populations with obesity and comorbidities, such as type 2 diabetes (25), cardiovascular disease (26), and knee osteoarthritis (27).”
Kasaie, P., Zhao, Y., Humes, E., Gerace, L., Reid, K. A., Lesko, C. R., Kurgansky, K. E., Koethe, J. R., Rebeiro, P. F., Bourgi, K., et al. (2025) · medRxiv · doi:10.1101/2025.11.05.25339607
Pharmacologic management of diabetes in older adults
Sia, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00007-2
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658 · Cited by 1
Nasir, L., Jalal, L., Siddiqa, A., Nasir, A., Farooqui, M., & Siddiqui, A. H. (2025) · European Journal of Therapeutics · doi:10.58600/eurjther2817
Guo, Z., Mao, X., Wang, Z., Lu, Y., Song, F., Chen, S., Di, J., Yan, Z., Tian, Z., & Xiang, C. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s550710
“In patients with KOA combined with OP, medial knee BMD”
Puszynski, M., & Ram, B. S. (2025) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000506 · Cited by 1
The interplay of stress, pain, and lifestyle: a Danish cross-sectional study of young adults
Sweka, T. S., Skov, M., Andersen, A. M. S., Lavesen, E. R., Petersen, K. K., & Hertel, E. (2025) · European Journal of Physiotherapy · doi:10.1080/21679169.2025.2604262
Continuidad asistencial en la atención clínica de la obesidad
Bretón, I., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501658 · Cited by 2
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés
Al-Aly, Z. (2025) · The Conversation · doi:10.64628/aak.6yfappa4p
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
From Repair to Prevention: The Emerging Role of Preventive Orthopedics
Martinez, H. E. L., Lugo, J. P. B., Vélez-Ramos, L., Saigal, A. N., & Señeriz-Ortiz, R. (2025) · Cureus · doi:10.7759/cureus.100008 · Cited by 1
Diabetische Polyneuropathie rechtzeitig erkennen und behandeln
Bönhof, G. J. (2026) · Die Diabetologie · doi:10.1007/s11428-025-01408-9
Ma, Q., Shang, X., Zhang, X., Nie, X., & Lu, L. (2026) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-25-00212
Wang, W., Fortuna, R., Mayengbam, S., Seerattan, R. A., Mu, C., Rios, J. L., Abughazaleh, N., Mehrabany, E. V., Tuplin, E. W. N., Hart, D. A., et al. (2026) · medRxiv · doi:10.64898/2026.01.21.26344540
Vach, W., & Saxer, F. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108243
Zhang, B., Kong, L., Wang, Y., He, W., Yang, M., Zhang, X., Chen, X., Zhang, Y., Liu, B., Bai, M., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00990
Templeton, K. J., & Geoffroy, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00013-6
Drapkina, O. M., Nasonov, E. L., Livzan, M. A., Garbuzova, E. V., & Ershova, A. I. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2025-4620
The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Metadata
- Authors
- Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E.
- Affiliations
- University of Louisville (US)
- From the Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen (H. Bliddal, L.E.K.), and Novo Nordisk, Søborg (T.H.M., A.K., J.S.N., A.W.) — both in Denmark; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY (H. Bays); the Department of Nutrition, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris (S.C.); the Obesity Department, Capio St. Göran’s Hospital, and Medical Department at the Karolinska Institute, Stockholm (J.U.H.); the Department of Endocrinology, Obesity, and Nutrition, Vestfold Hospital Trust, Tønsberg, and the Department of Endocrinology, Morbid Obesity, and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo — both in Norway (J.H.); Centro de Investigación en Reumatología y Especialidades Médicas, Bogota, Colombia (P.V.S.); and the University of Toronto and York University, Toronto, McMaster University, Hamil...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1573-1583
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4403912607
- Cited by
- 440
- References
- 37
- Citations by year
- 2026: 235 · 2025: 197 · 2024: 8
- FWCI
- 141.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- semaglutide, knee osteoarthritis, obesity, GLP-1 receptor agonists, weight loss, osteoarthritis pain, physical function, hypocaloric diet, physical activity counseling, adverse events, serious adverse events, drug safety, quality of life, Western Ontario and McMaster Universities Osteoarthritis Index, SF-36
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Combined Modality Therapy, Counseling, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Pain Measurement, Weight Loss, Body Mass Index, Arthralgia, Osteoarthritis, Knee, Caloric Restriction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.